Heyholder
‹ Activism Filings

JEIL PHARMA HOLDINGS INC. Q3 operating loss of KRW 3.4 billion, revenue KRW 156.7 billion, swinging to a loss

JEIL PHARMA HOLDINGS INC.· Periodic Report

AI summary · Not investment advice

In Q3, Jeil Pharma Holdings sold KRW 156.7 billion worth and lost KRW 3.4 billion from its main business, after earning KRW 18.1 billion a year earlier.

Operating profit · 3 months

KRW -3.4 billion

Key facts

Revenue (3 months)
KRW 156.7 billion
Net income (3 months)
KRW -9.4 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 161.4 billion
Revenue (year to date)
KRW 471.8 billion
Operating profit (prior-year 3 months)
KRW 18.1 billion
Operating profit (year to date)
KRW -9.8 billion
Net income (prior-year 3 months)
KRW 14.2 billion
Net income (year to date)
KRW -11.1 billion

Commentary

AI commentary · Not investment advice

What happened

Jeil Pharma Holdings reported its consolidated results for the third quarter of 2026. Sales for the latest 3 months were KRW 156.7 billion. That is 2.9% lower than the same 3 months a year earlier and 4.8% lower than the previous quarter.

In the company's terms

Operating profit (money earned from the core business) for the 3 months was a loss of KRW 3.4 billion, a swing from a profit of KRW 18.1 billion a year earlier. Net income (the final profit after taxes and all other costs) was a loss of KRW 9.4 billion, also a swing from a profit of KRW 14.2 billion a year earlier.

What changes for shareholders

For the year to date, from January 1 to September 30, sales were KRW 471.8 billion. Operating profit was a loss of KRW 9.8 billion. Net income was a loss of KRW 11.1 billion.

Comments

No comments yet

Comments from shareholders will appear here.